Our integrated suite of technologies allows us to paint a full picture of the immune synapse to analyze how TCRs recognize their respective and unique antigens, learning which T cells see which antigens in an individual’s MHC. Rather than relying on predictive epitopes, we use experimental systems to find real epitopes that bind to TCRs. We detect TCR-antigen pairs that interact and have a unique function. We determine the functional importance of T cells that recognize those unique peptides.
Our DECODETM platform also enables us to conduct clinical trials in a fundamentally different, more efficient manner. We create the right clonotype-specific product for the right group of patients and verify that the right medicine is getting to diseased tissue; this enables small, efficient proof-of-biology human trials.
MEDi, our mammalian epitope display platform, allows us to determine which peptides within a given protein can be presented on the surface of the antigen presenting cell, and the relative presentation potential across human leukocyte antigens (HLAs). The MEDi platform helps determine the peptides to be included in a therapy to ensure high levels of presentation across patient populations.
MCR enables unbiased screening of the reactivity of T cells. Our reporter cell lines cover most of the HLAs class II alleles, so patient genetics is not a limitation. With that coverage, the MCR platform, allow us to “see what the T cell sees.”
CIPHER, our tetramer-based pMHC libraries, are DNA-barcoded to enable the detection of T cells reactive to particular antigenic peptides. CIPHER technology is well developed against numerous CD8 HLAs, so MCR and CIPHER together enable detection of antigen-TCR pairs for both CD4 and CD8 T cells.
CAPTAN is our suite of internally developed deep learning computational tools that predicts TCR reactivity and leverages data from CIPHER and MEDi/MCR.
With our suite of technologies, we have the ability to design and develop targeted immune medicines.
View Pipeline